Trial Profile
Phase 2 study of modified formulation of LIPO-202 in patients with central abdominal bulging
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2018
Price :
$35
*
At a glance
- Drugs Salmeterol (Primary)
- Indications Subcutaneous fat disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Evofem Biosciences; Neothetics
- 05 Feb 2018 Planned initiation date changed from 1 Jul 2016 to 1 Dec 2016.
- 17 Jan 2018 According to an Evofem Biosciences media release, Evofem Biosciences merged with Neothetics to form Evofem Biosciences
- 10 Nov 2016 According to a Neothetics media release, based on the results of a trial (see profile 269605) in patients with fat deposits under the chin (submental fat) company will initiate this study.